Diploma revenue rises 21% to £1.84bn with 12% growth forecast for next year
The FTSE 100 group expects acquisitions already agreed to supply half of next year's growth, with its biggest division selling into aerospace, defence, datacentres and energy.
By Daily Oracles News Team2 min read
Diploma, the FTSE 100 supplier of specialist seals, controls and life sciences products, is forecasting revenue growth of about 12% at constant currency for the year to September 2027.
In the 12 months to 30 September revenue rose 21% to £1,840.3m, from £1,524.5m. Adjusted operating profit rose 42% to £487.1m, lifting the adjusted operating margin to 26.5% from 22.5%. Statutory operating profit was £390.0m, against £283.7m a year earlier, and adjusted earnings per share rose 45% to 255.6p.
Next year's guidance
The 12% splits roughly in two. Diploma expects organic growth of 6%, with double-digit growth in the first quarter slowing from the second quarter as it comes up against very strong figures from a year earlier. The other 6% comes from acquisitions announced so far, and that share would rise if it makes further acquisitions. The target operating margin of 25.5% is slightly below this year's, reflecting spending to support growth and the effect of newly acquired companies.
Since the start of the 2026 financial year the group has bought 16 businesses for about £368m, which together add about £50m of annual operating profit. Two of those deals, costing about £87m, were completed after the year end. Recent purchases include CDM, a US interconnect business serving defence with revenue of about $80m, and Elite Manufacturing Systems, a US supplier of aftermarket pump parts for the water and energy markets.
The three divisions
Controls, which made 61% of group revenue, grew 25% organically. Diploma said demand was strong across aerospace, defence, datacentres and energy, and that Windy City, Peerless, Clarendon and IS Group all grew by double digits.
Seals, at 26% of revenue, grew 4% organically, with high single-digit growth in North America and developments in nuclear power generation and water management.
Life Sciences, the smallest division at 13% of revenue, grew 1%. The company said healthcare markets were tough in the second half and expects the first half of the new financial year to stay challenging, though it described the longer-term prospects as attractive.
Cash and dividend
Free cash flow was £323.3m, a conversion rate of 94%, and the company's leverage ratio fell to 0.7 times from 0.8 times. The board has proposed a final dividend of 46.3p, making 65.4p for the year against 62.3p. Shares go ex-dividend on 14 January 2027 and the payment is due on 29 January to shareholders on the register on 15 January, subject to approval at the annual meeting on 13 January.




